JP Morgan Chase
PRCT icon

JP Morgan Chase’s Procept Biorobotics PRCT Stock Holding History

JP Morgan Chase’s Portfolio PRCT Stock Details PRCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-25,000
Closed -$1.44M – 7657
2025
Q2 		$1.44M Hold
25,000
– – ﹤0.01% 4147
2025
Q1 		$1.46M Buy
+25,000
New +$1.71M ﹤0.01% 4090

Other funds holding PRCT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BNP Paribas Asset Management
BNP Paribas Asset Management Paris, France $99.8B AUM 45.22% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
CC
Chicago Capital Chicago, Illinois $4.15B AUM 31.09% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

JP Morgan Chase's PRCT Position: Q2 2026 in Review

JP Morgan Chase increased its Procept Biorobotics (PRCT) stake by 3.2% in Q2 2026, buying an estimated $217K and bringing the position to 279,908 shares worth $6.38M. The position accounts for ﹤0.01% of the portfolio, ranked #3221.

JP Morgan Chase first reported a position in PRCT in Q4 2021 and has held it in 19 quarters since. The position peaked at $65.1M in Q3 2024. 253 funds tracked by Wall St. Rank hold PRCT as of Q2 2026.

  • JP Morgan Chase held 279,908 shares of Procept Biorobotics worth $6.38M as of Q2 2026.
  • JP Morgan Chase bought 8,677 Procept Biorobotics shares in Q2 2026, an estimated $217K.
  • Procept Biorobotics made up ﹤0.01% of JP Morgan Chase's portfolio in Q2 2026, its #3221 holding.
  • JP Morgan Chase first reported a position in Procept Biorobotics in Q4 2021 and has held it in 19 quarters since.
  • JP Morgan Chase's Procept Biorobotics position peaked at $65.1M in Q3 2024.
  • 253 funds tracked by Wall St. Rank held Procept Biorobotics as of Q2 2026.

Based on JP Morgan Chase's 13F filing for Q2 2026, filed 12 Aug 2026.